Chengda biology: transfer relevant assets of Benxi human vaccine base to a wholly-owned subsidiary
Chengda biology announced that the board of directors agreed that the company would transfer the assets and liabilities related to Benxi human vaccine business to Chengda Biology (Benxi) Co., Ltd., a wholly-owned subsidiary, according to the net book value on January 31, 2022; At the same time, the implementation subject of the raised investment project "human vaccine phase I construction project of Benxi Branch of Liaoning Chengda biology Co., Ltd." was changed from "Benxi Branch of Chengda biology" to "Benxi subsidiary".
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 06, 2023 08:30 AM
Jan 05, 2023 07:33 PM
Briefing Feb 17, 2022 10:08 AM
Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway
Healthcare, Financials
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Briefing Jan 24, 2022 02:39 PM
The main force continued to increase its position in lithium battery stocks in the late trading, and sold off banks and pharmaceutical stocks
Briefing Jan 14, 2022 02:18 PM
· Healthcare
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
Chinese Cuisine Brand YGF Malatang Ventures into Brazil
Apr 23, 2024 02:21 PM